The latest price target for ITeos Therapeutics (NASDAQ:ITOS) was reported by HC Wainwright & Co. on September 16, 2024. The analyst firm set a price target for $46.00 expecting ITOS to rise to within 12 months (a possible 309.25% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for ITeos Therapeutics (NASDAQ:ITOS) was provided by HC Wainwright & Co., and ITeos Therapeutics reiterated their buy rating.

There is no last upgrade for ITeos Therapeutics

There is no last downgrade for ITeos Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a reiterated with a price target of $46.00 to $46.00. The current price ITeos Therapeutics (ITOS) is trading at is $11.24, which is out of the analyst’s predicted range.